St. James Investment Company LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 9.2% during the second quarter, Holdings Channel reports. The fund owned 7,299 shares of the company’s stock after buying an additional 616 shares during the period. St. James Investment Company LLC’s holdings in Johnson & Johnson were worth $885,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently made changes to their positions in the company. Stratford Consulting LLC raised its position in shares of Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 3,201 shares of the company’s stock worth $388,000 after buying an additional 18 shares during the last quarter. Gateway Advisory LLC increased its position in Johnson & Johnson by 0.5% in the first quarter. Gateway Advisory LLC now owns 4,215 shares of the company’s stock worth $456,000 after buying an additional 23 shares in the last quarter. Bollard Group LLC increased its position in Johnson & Johnson by 0.7% in the second quarter. Bollard Group LLC now owns 3,895 shares of the company’s stock worth $473,000 after buying an additional 27 shares in the last quarter. Armbruster Capital Management Inc. increased its position in Johnson & Johnson by 0.7% in the second quarter. Armbruster Capital Management Inc. now owns 4,438 shares of the company’s stock worth $538,000 after buying an additional 30 shares in the last quarter. Finally, Amarillo National Bank increased its position in Johnson & Johnson by 0.6% in the second quarter. Amarillo National Bank now owns 5,496 shares of the company’s stock worth $667,000 after buying an additional 35 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE:JNJ) traded down 1.78% during mid-day trading on Thursday, hitting $117.27. 6,128,639 shares of the company traded hands. Johnson & Johnson has a one year low of $91.76 and a one year high of $126.07. The firm has a 50 day moving average of $119.56 and a 200 day moving average of $116.58. The firm has a market capitalization of $320.84 billion, a P/E ratio of 21.85 and a beta of 0.61.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The business had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion. Equities research analysts expect that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 2.73%. The ex-dividend date was Friday, August 19th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.15%.
A number of equities analysts have recently commented on JNJ shares. BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research note on Friday, June 3rd. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $109.97 price objective for the company. in a research note on Monday, June 6th. Wells Fargo & Co. restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, June 6th. Goldman Sachs Group Inc. set a $121.00 price objective on shares of Johnson & Johnson and gave the stock a “neutral” rating in a research note on Monday, June 13th. Finally, Jefferies Group restated a “hold” rating and set a $109.00 price objective (up from $108.00) on shares of Johnson & Johnson in a research note on Tuesday, June 14th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $120.19.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.